<DOC>
	<DOC>NCT01077804</DOC>
	<brief_summary>The purpose of these continuing post-licensure studies is to evaluate the long-term effectiveness of VARIVAXÂ® [Varicella Virus Vaccine Live (Oka/Merck)] and to assess the impact of the vaccine on the epidemiology of varicella and herpes zoster.</brief_summary>
	<brief_title>A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED)</brief_title>
	<detailed_description>Parents/guardians of the cohort of children vaccinated between 12 and 23 months of age during a six-month period in 1995 (June-November) at KPMCP Northern California were interviewed by telephone at 6-month intervals to ascertain whether their child had varicella or herpes zoster in the 6 months prior to interview. Follow-up continued for a minimum of 14 years after vaccination.</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Subject was a member of Kaiser Permanente Northern California, age 1223 months, received a dose of varicella vaccine between June and November 1995, and parents accepted to participate in 15year followup Subjects diagnosed with varicella before study enrollment Subject's parents unable to complete telephone interviews in English, Spanish, or Cantonese</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>